XM bietet keine Dienstleistungen für Personen mit Wohnsitz in den Vereinigten Staaten von Amerika an.

XM bietet keine Dienstleistungen für Personen mit Wohnsitz in den Vereinigten Staaten von Amerika an.
T
T

Teva

Nachrichten

Reuters - vor 2 Wochen

Teva Pharma's listed shares up after company lifts 2024 forecasts

BUZZ-Teva Pharma's US-listed shares up after company lifts 2024 forecasts ** U.S.-listed shares TEVA.N of Israel-based Teva Pharmaceutical rise 4.5% to $17.2 premarket ** Company raises its FY forecasts as it benefits from strong demand for its cheaper generic medicines and branded treatment for Huntington's disease (HD) ** TEVA is banking on its b
T
Reuters - vor 2 Wochen

Teva Pharmaceutical Industries Ltd reports results for the quarter ended in June - Earnings Summary

Teva Pharmaceutical Industries Ltd reports results for the quarter ended in June - Earnings Summary Teva Pharmaceutical Industries Ltd TEVA.TA reported quarterly adjusted earnings of 61 cents​​ per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of 56 cents. The mean expectation of four analysts for the quarter was for earnings of 57 cents per share.
T
Reuters - vor 2 Wochen

Teva boosts forecasts as sales of generics, Huntington's disease drug jump

UPDATE 3-Teva boosts forecasts as sales of generics, Huntington's disease drug jump Adds details from conference call in paragraphs 4,5,6 and 7; analyst comment in paragraph 15, graphic By Bhanvi Satija and Michael Erman July 31 (Reuters) - Teva Pharmaceutical Industries TEVA.N raised its annual forecasts on Wednesday, banking on strong demand for its cheaper copycat medicines, including a GLP-1 generic, and branded treatment for Huntington's disease.
T
Reuters - vor 2 Wochen

Teva Pharma lifts annual profit view on strong generic, Huntington's disease drug sales

Teva Pharma lifts annual profit view on strong generic, Huntington's disease drug sales July 31 (Reuters) - Teva Pharmaceutical Industries TEVA.N raised its full-year profit forecast on Wednesday, banking on strength in its generic drug business and strong sales of its Huntington's disease drug. Teva now expects its profit for the full year 2024 to be between $2.30 and $2.50 per share, compared with its previous expectation of $2.20-$2.50 per share.
T
Reuters - vor 2 Wochen

Teva Pharmaceutical Industries Ltd <TEVA.N> expected to post earnings of 55 cents a share - Earnings Preview

Teva Pharmaceutical Industries Ltd expected to post earnings of 55 cents a share - Earnings Preview Teva Pharmaceutical Industries Ltd TEVA.N , TEVA.K is expected to show a rise in quarterly revenue when it reports results on July 31 for the period ending June 30 2024 The Tel Aviv-yafo Israel-based company is expected to report a 4.6% increase in revenue to $4.056 billion from $3.88 billion a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
T
Reuters - vor 3 Wochen

Court weighs what US must prove in Regeneron kickback case

Court weighs what US must prove in Regeneron kickback case By Nate Raymond July 22 (Reuters) - The U.S. Department of Justice on Monday urged a federal appeals court to overturn a judge's ruling that made it tougher for the government to win a lawsuit against Regeneron Pharmaceuticals REGN.O and prove the drugmaker engaged in an illegal kickback scheme.
R
T
Reuters - vor 4 Wochen

Teva Announces First Phase 3 Evidence Of Efficacy And Safety Of An Anti-Cgrp Monoclonal Antibody In Children In Ajovy® (Fremanezumab) Space Trial For Prevention Of Episodic Migraine

BRIEF-Teva Announces First Phase 3 Evidence Of Efficacy And Safety Of An Anti-Cgrp Monoclonal Antibody In Children In Ajovy® (Fremanezumab) Space Trial For Prevention Of Episodic Migraine July 18 (Reuters) - Teva Pharmaceutical Industries Ltd TEVA.TA : TEVA ANNOUNCES FIRST PHASE 3 EVIDENCE OF EFFICACY AND SAFETY OF AN ANTI-CGRP MONOCLONAL ANTIBODY
T
Reuters - vor 1 Monat

US DOJ drops Viatris unit Mylan from industry-wide antitrust probe

UPDATE 2-US DOJ drops Viatris unit Mylan from industry-wide antitrust probe Adds background in paragraphs 2,5 and 6, updates share movement July 2 (Reuters) - Viatris VTRS.O u nit Mylan is no longer a subject of the U.S. Department of Justice's antitrust investigation into alleged price fixing in the generic drug industry , the parent company said on Tuesday.
P
T
Reuters - vor 2 Monaten

FTC starts probe into Teva about some products' patents, Washington Post reports

UPDATE 2-FTC starts probe into Teva about some products' patents, Washington Post reports Adds Teva comment in penultimate paragraph, background in last paragraph July 1 (Reuters) - The U.S. Federal Trade Commission has opened an investigation into Teva Pharmaceutical TEVA.TA over the company's refusal to take down about two dozen patents for its asthma and COPD inhalers, the Washington Post reported on Monday, citing agency documents.
T
Reuters - vor 2 Monaten

Drugmaker Servier loses EU court fight over pay-for-delay deals

UPDATE 1-Drugmaker Servier loses EU court fight over pay-for-delay deals Adds details By Foo Yun Chee BRUSSELS, June 27 (Reuters) - French drugmaker Servier on Thursday lost its court battle against a European Union fine for deals with rivals to delay sales of generic copies of its top-selling blood pressure medicine perindopril. The European Commission fined Servier 331 million euros ($354 million) in 2014 - and also fined generic drugmakers Teva TEVA.TA , Unichem and its subsidiary Niche, Matr
T
Reuters - vor 2 Monaten

EU top court rejects Servier appeal against EU antitrust fine

EU top court rejects Servier appeal against EU antitrust fine BRUSSELS, June 27 (Reuters) - Europe's top court on Thursday rejected French drugmaker Servier's appeal against a finding by EU antitrust regulators a decade ago that its pay-for-delay deals with generic rivals were anti-competitive. "The Court dismisses the appeals of Lupin, Niche Generics, Unichem Laboratories, Matrix, Teva and Biogaran.
T
Reuters - vor 2 Monaten

Alert wrongly tagged to Teva Pharmaceutical withdrawn

ADVISORY-Alert wrongly tagged to Teva Pharmaceutical withdrawn An alert on Deckers Brands' DECK.N unit Teva was incorrectly tagged to Teva Pharmaceutical Industries TEVA.TA , TEVA.N , an unrelated company, and has been withdrawn. There will be no substitute. STORY_NUMBER: nTUABMJBL2 STORY_DATE: June 26, 2024 STORY_TIME: 01:00:13 PM GMT
T
Reuters - vor 2 Monaten

Teva Reaches Agreement With The Israel Tax Authority To Resolve All Pending Litigation For The Company's Taxable Years 2008-2020

BRIEF-Teva Reaches Agreement With The Israel Tax Authority To Resolve All Pending Litigation For The Company's Taxable Years 2008-2020 June 25 (Reuters) - Teva Pharmaceutical Industries Ltd TEVA.TA : TEVA REACHES AGREEMENT WITH THE ISRAEL TAX AUTHORITY TO RESOLVE ALL PENDING LITIGATION FOR THE COMPANY'S TAXABLE YEARS 2008-2020 TEVA: WILL PAY A TOTA
T
Reuters - vor 2 Monaten

Teva settles tax dispute in Israel with $750 mln payment

UPDATE 1-Teva settles tax dispute in Israel with $750 mln payment Adds details in paragraphs 3 & 4 June 25 (Reuters) - Teva Pharmaceutical Industries TEVA.TA has entered into a deal with the Israel Tax Authority to resolve all pending litigation related to taxes payable for the years from 2008 to 2020, the drugmaker said on Tuesday. Under the agreement, Teva will pay $750 million in installments between 2024 and 2029. In future, if Teva pays dividends on, or repurchases, its equity interests, th
T
Reuters - vor 2 Monaten

Teva reaches agreement to resolve pending tax litigations for $750 million

Teva reaches agreement to resolve pending tax litigations for $750 million June 25 (Reuters) - Teva Pharmaceutical Industries TEVA.TA said on Tuesday it has entered an agreement with the Israel Tax Authority to resolve all pending litigation regarding taxes payable for the years from 2008 to 2020. Under the agreement, the Israel-based company will
T
Reuters - vor 2 Monaten

US law firm Motley Rice appeals $396 mln opioid fee award

US law firm Motley Rice appeals $396 mln opioid fee award By Brendan Pierson June 24 (Reuters) - U.S. law firm Motley Rice is appealing its award of $396 million for its work on litigation against the drug industry over the opioid crisis that resulted in $46 billion in nationwide settlements. The firm said it would appeal the award, which represents 18.6% of a $2.13 billion pool of fees to be divided among dozens of law firms, in a notice filed Friday in Cleveland federal court.
T
W
M
Reuters - vor 2 Monaten

Teva launches generic version of Novo Nordisk's diabetes drug Victoza

UPDATE 2-Teva launches generic version of Novo Nordisk's diabetes drug Victoza Adds details on Victoza in paragraphs 4 to 6 June 24 (Reuters) - Teva Pharmaceuticals TEVA.TA said on Monday it had launched a generic version of Novo Nordisk's NOVOb.CO Victoza to treat patients with type 2 diabetes, making it the first generic GLP-1 drug in the United States where the drug class has seen overwhelming demand .
H
T
Reuters - vor 2 Monaten

Teva launches generic version of Novo Nordisk's diabetes drug Victoza

Teva launches generic version of Novo Nordisk's diabetes drug Victoza June 24 (Reuters) - Teva Pharmaceuticals TEVA.TA said on Monday it has launched the generic version of Danish drugmaker Novo Nordisk's NOVOb.CO drug Victoza to treat patients with type 2 diabetes. The U.S. Food and Drug Administration on Friday tentatively approved London-based Hikma Pharmaceuticals' HIK.L version of Victoza, according to the agency's website.
H
T
Reuters - vor 2 Monaten

Teva Announces Launch Of Authorized Generic Of Victoza In The U.S.

BRIEF-Teva Announces Launch Of Authorized Generic Of Victoza In The U.S. June 24 (Reuters) - Teva Pharmaceutical Industries Ltd TEVA.TA : TEVA ANNOUNCES LAUNCH OF AUTHORIZED GENERIC OF VICTOZA® (LIRAGLUTIDE INJECTION 1.8MG), IN THE UNITED STATES TEVA: LIRAGLUTIDE INJECTION IS INDICATED TO IMPROVE GLYCEMIC CONTROL IN ADULTS AND PEDIATRIC PATIENTS A
T
Reuters - vor 2 Monaten

Drugmaker Apotex accuses Amarin of Vascepa monopoly in US lawsuit

Drugmaker Apotex accuses Amarin of Vascepa monopoly in US lawsuit By Mike Scarcella June 17 (Reuters) - Drugmaker Apotex has sued its rival Amarin > in federal court in New Jersey, accusing it of thwarting competition for a generic version of its heart drug Vascepa and causing wholesalers and other buyers to pay artificially higher prices. The lawsuit , filed on Friday, said Amarin “has engaged in a calculated anticompetitive scheme” for more than a decade to protect Vascepa from drugmakers
B
T

Konditionen

Beliebte Finanzwerte

Rechtlicher Hinweis: Die Unternehmen der XM Group bieten Dienstleistungen ausschließlich zur Ausführung an sowie Zugang zu unserer Online-Handelsplattform. Durch diese können Personen die verfügbaren Inhalte auf oder über die Internetseite betrachten und/oder nutzen. Eine Änderung oder Erweiterung dieser Regelung ist nicht vorgesehen und findet nicht statt. Der Zugang wird stets geregelt durch folgende Vorschriften: (i) Allgemeine Geschäftsbedingungen; (ii) Risikowarnungen und (iii) Vollständiger rechtlicher Hinweis. Die bereitgestellten Inhalte sind somit lediglich als allgemeine Informationen zu verstehen. Bitte beachten Sie, dass die Inhalte auf unserer Online-Handelsplattform keine Aufforderung und kein Angebot zum Abschluss von Transaktionen auf den Finanzmärkten darstellen. Der Handel auf Finanzmärkten birgt ein hohes Risiko für Ihr eingesetztes Kapital.

Sämtliche Materialien, die auf unserer Online-Handelsplattform veröffentlicht sind, dienen ausschließlich dem Zweck der Weiterbildung und Information. Die Materialien beinhalten keine Beratung und Empfehlung im Hinblick auf Finanzen, Anlagesteuer oder Handel und sollten nicht als eine dahingehende Beratung und Empfehlung aufgefasst werden. Zudem enthalten die Materialien keine Aufzeichnungen unserer Handelspreise sowie kein Angebot und keine Aufforderung für jegliche Transaktionen mit Finanzinstrumenten oder unverlangte Werbemaßnahmen für Sie zum Thema Finanzen. Die Materialien sollten auch nicht dahingehend aufgefasst werden.

Alle Inhalte von Dritten und die von XM bereitgestellten Inhalte sowie die auf dieser Internetseite zur Verfügung gestellten Meinungen, Nachrichten, Forschungsergebnisse, Analysen, Kurse, sonstigen Informationen oder Links zu Seiten von Dritten werden ohne Gewähr bereitgestellt. Sie sind als allgemeine Kommentare zum Marktgeschehen zu verstehen und stellen keine Anlageberatung dar. Soweit ein Inhalt als Anlageforschung aufgefasst wird, müssen Sie beachten und akzeptieren, dass der Inhalt nicht in Übereinstimmung mit gesetzlichen Bestimmungen zur Förderung der Unabhängigkeit der Anlageforschung erstellt wurde. Somit ist der Inhalt als Werbemitteilung unter Beachtung der geltenden Gesetze und Vorschriften anzusehen. Bitte stellen Sie sicher, dass Sie unseren Hinweis auf die nicht unabhängige Anlageforschung und die Risikowarnung im Hinblick auf die vorstehenden Informationen gelesen und zur Kenntnis genommen haben, die Sie hier finden.

Risikowarnung: Es bestehen Risiken für Ihr eingesetztes Kapital. Gehebelte Produkte sind nicht für alle Anleger geeignet. Bitte beachten Sie unseren Risikohinweis.